A Seamless Phase 2A-B Randomized Double-Blind Placebo Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients with Mild to Moderate Alzheimer's Disease

PI:  Tom Ala, MD

Study Contact:  Barbara Cray Lokaitis, BA, CCRP          217.545.9737

A Phase 2 Multiple Dose, Multicenter, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects with Early Alzheimer's Disease

PI:  Tom Ala, MD

Study Contact:  Laura Reiser, RN, BSN          217.545.2261

An Extension Study of ABBV-8E12 in Early Alzheimer's Disease

PI:  Tom Ala, MD

Study Contact:  Laura Reiser, RN, BSN        217.545.2261

A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Prodromal to Mild Alzheimer's Disease

PI:  Tom Ala, MD

Study Contact:  Barbara Cray Lokaitis, BA, CCRP          217.545.9737

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Study of Gantenerumab in Patients With Early (Prodromal to Mild) Alzheimer's Disease - WN29922

PI:  Tom Ala, MD

Study Contact:  Barbara Cray Lokaitis, BA, CCRP          217.545.9737

Caregiver Characteristics That May Predict When Patients With Alzheimer's Disease Are Placed in Long-term Care Facilities

PI:  Tom Ala, MD

Study Contact:  Stephanie Kohlrus, BA, CCRP          217.545.3013

Alzheimer's Disease Initiative - Specialized Supportive Services

PI:  Tom Ala, MD

Study Contact:   Barbara Cray Lokaitis, BA, CCRP          217.545.9737